Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Changing the South African national antiretroviral therapy guidelines: The role of cost modelling.

Meyer-Rath G, Johnson LF, Pillay Y, Blecher M, Brennan AT, Long L, Moultrie H, Sanne I, Fox MP, Rosen S.

PLoS One. 2017 Oct 30;12(10):e0186557. doi: 10.1371/journal.pone.0186557. eCollection 2017.

2.

The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.

Hontelez JA, de Vlas SJ, Tanser F, Bakker R, Bärnighausen T, Newell ML, Baltussen R, Lurie MN.

PLoS One. 2011;6(7):e21919. doi: 10.1371/journal.pone.0021919. Epub 2011 Jul 20.

3.

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.

Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walensky RP.

Clin Infect Dis. 2013 Feb;56(4):587-97. doi: 10.1093/cid/cis887. Epub 2012 Oct 19.

4.

The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.

Dutta A, Barker C, Kallarakal A.

PLoS Med. 2015 Nov 24;12(11):e1001907; discussion e1001907. doi: 10.1371/journal.pmed.1001907. eCollection 2015 Nov.

5.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

6.

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.

7.

Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.

Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, Hallett TB, Barnabas RV.

Lancet HIV. 2015 Apr;2(4):e159-68.

8.

Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.

Barker C, Dutta A, Klein K.

J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648. doi: 10.7448/IAS.20.5.21648.

9.

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP; CEPAC-International and OCTANE Investigators.

AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe.

10.
11.

Antiretroviral therapy needs: the effect of changing global guidelines.

Stanecki K, Daher J, Stover J, Beusenberg M, Souteyrand Y, García Calleja JM.

Sex Transm Infect. 2010 Dec;86 Suppl 2:ii62-6. doi: 10.1136/sti.2010.046177.

12.

Implementing universal HIV treatment in a high HIV prevalence and rural South African setting - Field experiences and recommendations of health care providers.

Plazy M, Perriat D, Gumede D, Boyer S, Pillay D, Dabis F, Seeley J, Orne-Gliemann J.

PLoS One. 2017 Nov 20;12(11):e0186883. doi: 10.1371/journal.pone.0186883. eCollection 2017.

13.

Annual cost of antiretroviral therapy among three service delivery models in Uganda.

Vu L, Waliggo S, Zieman B, Jani N, Buzaalirwa L, Okoboi S, Okal J, Borse NN, Kalibala S.

J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20840. doi: 10.7448/IAS.19.5.20840. eCollection 2016.

14.

The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.

Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, Churchyard G, Watts C, Vickerman P.

PLoS Med. 2015 Sep 1;12(9):e1001869. doi: 10.1371/journal.pmed.1001869. eCollection 2015 Sep.

15.

The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.

Wolf LL, Ricketts P, Freedberg KA, Williams-Roberts H, Hirschhorn LR, Allen-Ferdinand K, Rodriguez WR, Divi N, Wong MT, Losina E.

J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):463-71.

16.

Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.

Leisegang R, Cleary S, Hislop M, Davidse A, Regensberg L, Little F, Maartens G.

PLoS Med. 2009 Dec;6(12):e1000189. doi: 10.1371/journal.pmed.1000189. Epub 2009 Dec 1.

17.

Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa.

Bor J, Fox MP, Rosen S, Venkataramani A, Tanser F, Pillay D, Bärnighausen T.

PLoS Med. 2017 Nov 28;14(11):e1002463. doi: 10.1371/journal.pmed.1002463. eCollection 2017 Nov.

18.

Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.

Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA; CEPAC-International Investigators.

PLoS Med. 2010 Dec 21;7(12):e1000382. doi: 10.1371/journal.pmed.1000382.

19.

Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.

Holmes CB, Zheng H, Martinson NA, Freedberg KA, Walensky RP.

Clin Infect Dis. 2006 Jun 15;42(12):1772-80. Epub 2006 May 12.

PMID:
16705586
20.

Implications of adopting new WHO guidelines for antiretroviral therapy initiation in Ethiopia.

Konings E, Ambaw Y, Dilley K, Gichangi P, Arega T, Crandall B.

Bull World Health Organ. 2012 Sep 1;90(9):659-63. doi: 10.2471/BLT.11.089599. Epub 2012 Jun 25.

Supplemental Content

Support Center